Leo Creative

  • Home
  • About
  • Our Approach
  • Our Work
    • Branding
    • Healthcare
  • Contact

Launching a new treatment for Dupuytren’s contracture

Client: Janssen Australia

dupuytens

Leo Creative worked with Janssen on the Australian launch of collagenase – a non-surgical TGA approved treatment for Dupuytren’s contracture. Like most pharma branding, the creative was done overseas, so the task was to adapt global brand assets for the local Australia market.

A wide range of collateral was produced including mandatory items like product information and consumer medicine information, printed detail aid and e-detailer (Veeva iRep), physician and patient guides.

Filed Under: work

An online resource for AbbVie’s Virology Sales Team

Client: AbbVie Australia AbbVie approached Leo Creative with a specific problem. In a highly competitive environment and an abundance of existing and new research, how can we ensure our in-field … MORE

A new direction in the treatment of Peyronie’s disease

Client: Janssen Australia When Janssen was granted a second indication for collagenase clostridium histolyticum by the Therapeutic Goods Administration – for the treatment of Peyronie’s disease – … MORE

Veeva iRep v Next Interact

After delivering our first project targeting Veeva’s iRep platform, here are some initial thoughts on creating content for these two widely used apps. In many ways comparing Next Interact with Veeva … MORE

The role of branding in highly specialised markets

In our post “What we believe about pharma branding”, we gave a brief overview of the history of branding and the adoption of the FMCG branding model by big pharma where value is driven by the … MORE

Copyright © 2026 Leo Creative Pty Ltd · Genesis Framework by StudioPress · Log in